Pseudoginsenoside-F11: a comprehensive review of chemical structure, pharmacological activities, pharmacokinetics, and therapeutic potential

L.), is characterized by a distinctive 20,24-epoxy bridge. This review summarizes the current evidence regarding PF11's chemical structure, pharmacological effects, pharmacokinetics, and therapeutic potential. Preclinical studies have demonstrated that PF11 exerts multi-targeted neuroprotective effects in animal models of Alzheimer's disease, Parkinson's disease, and cerebral ischemia. These neuroprotective actions are mediated through the regulation of calcium homeostasis, restoration of the autophagy-lysosomal pathway, and modulation of microglial polarization. Beyond neuroprotection, PF11 offers additional beneficial effects: it protects the heart by antagonizing the β1-adrenoceptor, safeguards the kidneys via inhibition of the NF-κB/NLRP3 pathway, regulates metabolism as a partial PPARγ agonist, and mitigates tolerance to morphine and methamphetamine. Despite promising preclinical evidence, PF11 remains at an early translational stage due to poor oral bioavailability, incomplete pharmacokinetic characterization, and the absence of human studies. Addressing these limitations through formulation optimization, mechanistic validation, and rigorous clinical investigation will determine whether PF11 can progress from a natural product lead to a viable therapeutic candidate.